In prostate cancer, EZH2 promotes progression via its dual roles: its canonical role in epigenetic silencing of tumor suppressor genes as well as its noncanonical role as a transcription factor in activating AR transcription [16, 17]. Here, EZH2 is linked to prostate carcinoma.